Stevanato Group S.p.A. (NYSE:STVN) Position Cut by Healthcare of Ontario Pension Plan Trust Fund

Healthcare of Ontario Pension Plan Trust Fund reduced its holdings in Stevanato Group S.p.A. (NYSE:STVN) by 43.3% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 33,100 shares of the company’s stock after selling 25,300 shares during the quarter. Healthcare of Ontario Pension Plan Trust Fund’s holdings in Stevanato Group were worth $1,063,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Natixis Advisors L.P. increased its holdings in shares of Stevanato Group by 1.9% during the fourth quarter. Natixis Advisors L.P. now owns 23,858 shares of the company’s stock valued at $651,000 after purchasing an additional 449 shares during the period. Personal CFO Solutions LLC raised its position in shares of Stevanato Group by 4.6% during the 4th quarter. Personal CFO Solutions LLC now owns 12,186 shares of the company’s stock worth $333,000 after buying an additional 534 shares in the last quarter. First Horizon Advisors Inc. lifted its stake in shares of Stevanato Group by 14.1% in the 4th quarter. First Horizon Advisors Inc. now owns 5,311 shares of the company’s stock worth $145,000 after acquiring an additional 657 shares during the period. Fifth Third Bancorp boosted its holdings in shares of Stevanato Group by 23.6% in the first quarter. Fifth Third Bancorp now owns 4,956 shares of the company’s stock valued at $159,000 after acquiring an additional 947 shares in the last quarter. Finally, PNC Financial Services Group Inc. boosted its holdings in shares of Stevanato Group by 54.2% in the fourth quarter. PNC Financial Services Group Inc. now owns 3,089 shares of the company’s stock valued at $84,000 after acquiring an additional 1,086 shares in the last quarter.

Stevanato Group Trading Down 9.0 %

STVN traded down €1.96 ($2.13) during midday trading on Thursday, reaching €19.79 ($21.51). The company’s stock had a trading volume of 2,312,479 shares, compared to its average volume of 512,532. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.35 and a current ratio of 1.92. The company has a fifty day simple moving average of €19.33 and a 200 day simple moving average of €25.96. Stevanato Group S.p.A. has a twelve month low of €16.56 ($18.00) and a twelve month high of €36.30 ($39.46).

Stevanato Group (NYSE:STVN) last posted its earnings results on Thursday, May 9th. The company reported €0.09 ($0.10) EPS for the quarter, missing the consensus estimate of €0.12 ($0.13) by (€0.03) (($0.03)). The company had revenue of €256.24 million for the quarter, compared to the consensus estimate of €261.28 million. Stevanato Group had a return on equity of 12.61% and a net margin of 12.57%. As a group, analysts expect that Stevanato Group S.p.A. will post 0.53 earnings per share for the current year.

Stevanato Group Announces Dividend

The company also recently disclosed an annual dividend, which was paid on Monday, July 15th. Investors of record on Tuesday, June 4th were given a $0.053 dividend. The ex-dividend date of this dividend was Tuesday, June 4th. This represents a yield of 0.29%. Stevanato Group’s payout ratio is 10.91%.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on STVN shares. BNP Paribas began coverage on Stevanato Group in a research report on Monday, April 22nd. They issued an “outperform” rating for the company. Morgan Stanley cut their price target on shares of Stevanato Group from $26.00 to $22.00 and set an “equal weight” rating for the company in a report on Monday, July 15th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, Stevanato Group currently has an average rating of “Moderate Buy” and an average price target of €32.83 ($35.69).

Stevanato Group Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.